USP9X Double Nickase Plasmid (h): sc-402285-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- USP9X Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- USP9X Double Nickase Plasmid (h) and USP9X Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting USP9X. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
USP9X Double Nickase Plasmid (h) | sc-402285-NIC | 20 µg | $410.00 | |||
USP9X Double Nickase Plasmid (h2) | sc-402285-NIC-2 | 20 µg | $410.00 |
USP9X encodes a large ubiquitin-specific protease that removes ubiquitin from protein substrates to regulate their stability, localization, and signaling output. USP9X participates in ubiquitin-dependent proteostasis and intersects with pathways controlling cell fate decisions, cell cycle progression, DNA damage responses, and stress signaling, including modulation of kinase and apoptosis-related networks. Through its deubiquitinating activity, USP9X influences endocytic trafficking and protein turnover of key regulatory factors, thereby shaping transcriptional programs and cellular homeostasis. Dysregulated USP9X expression or activity has been associated with altered signaling states observed across neurodevelopmental disorders and multiple cancer contexts, making it a frequent target in mechanistic studies of ubiquitin pathway biology.
USP9X Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the USP9X locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within USP9X. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt USP9X function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of USP9X-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.